Providers

Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.

Understanding the needs of gender-diverse patients and patients receiving gender-affirming hormones is crucial to equitable care and properly addressing patients' needs.

This retrospective review compared appendicular lean mass (ALM) and ALM index among patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD).

HADLIMA is currently indicated for psoriatic arthritis, plaque psoriasis, and hidradenitis suppurativa, among others.

A retrospective analysis suggested that administering rituximab to patients with rheumatoid arthritis complicated by lymphoma, systemic vasculitis, or extra-articular lesions was associated with improved outcomes.

Tirzepatide is already approved to treat type 2 diabetes, and is now approved for chronic weight management in adults with obesity or overweight with at least 1 weight-related condition.

Care in the fourth-trimester, when the birth has taken place and the mother and baby return home, is crucial for the well-being of the mother or the birthing person, Takiyah Durham, MBA, explains in an interview.

Three new novel treatments have shown promise in the treatment of multiple sclerosis (MS), including the potential to target neuroinflammation at its source.

When patients are undergoing treatment for cancer, clinicians should be aware of the potential to develop myasthenia gravis from immune checkpoint inhibitors (ICI), new research stresses, with ongoing surveillance and risk factor identification becoming necessary steps.

Rhenium (186Re) obisbemeda (Plus Therapeutics) shows potential to address the unmet need of new treatment options for patients with breast cancer and leptomeningeal metastases and will continue to be evaluated in the ReSPECT-LM program. The orphan drug designation (ODD) was granted on November 3.

Phathom Pharmaceuticals' vonoprazan (Voquenza) sets a new standard in erosive gastroesophageal reflux disease (GERD) therapy.

The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant consideration of pharmacotherapy, and 1 in 48 had high levels of LDL-C that are indicated for medication.

Presenters at American Society of Nephrology Kidney Week 2023 highlighted the importance of understanding the barriers faced by the LGBTQ+ community that impact kidney outcomes and the need to gather better data for studying these issues.

There is great value, both for clinical trials and clinical practice, in biomarkers that identify patients at greatest risk of developing chronic kidney disease (CKD) after acute kidney injury, explained Steven Coca, DO, MS, Icahn School of Medicine at Mount Sinai.

Presenters at the American Society of Nephrology (ASN) Kidney Week 2023 highlighted the exciting new technologies that nephrology research has developed to improve patient outcomes, quality of life, and approaches to care.

This newly developed prediction model evaluating community-acquired pneumonia risk was noted to demonstrate accuracy, strong discriminatory qualities, and practicability in clinical settings.

Posters at ASN Kidney Week 2023 explored the economic burden brought on by chronic kidney disease (CKD) and further validated the Klinrisk model’s ability to predict progressive forms of CKD.

The Enhancing Oncology Model is trying to address a number of the systemic challenges oncology faces without giving practices the tools and resources they need, said Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.

Pregnancies for patients on dialysis are high risk and care by a multidisciplinary team is extremely important for a successful birth, explained Silvi Shah, MD, MS, FASN, assistant professor, Division of Nephrology and Hypertension, University of Cincinnati.

Data shows sodium-glucose cotransporter-2 (SGLT2) inhibitors are efficacious and can be used in almost all common kidney diagnoses, explained William G. Herrington, MD, MA, MBBS, Nuffield Department of Population Health, University of Oxford.

Presenters at ASN Kidney Week 2023 emphasized the importance of patient education, awareness, and advocacy in the realm of kidney transplantation.

A retrospective study presented at the 2023 American Association of Neuromuscular and Electrodiagnotsic Medicine meeting revealed that social determinants of health (SDOH) are linked to poorer treatment outcomes in patients who have myasthenia gravis, emphasizing the need for identifying and supporting at-risk individuals.

For patients with chronic kidney disease, dose adjustments for other medications requires coordination with other specialists to maintain treatment efficacy, explained Linda Awdishu, PharmD, FASN, professor and division head of clinical pharmacy at the University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences.

Two posters presented at Kidney Week 2023 evaluated the global state of chronic kidney disease (CKD) and shed light on delays in CKD diagnoses in the United States.

Presenters at the American Society of Nephrology's Kidney Week 2023 discussed the past, present, and future of pediatric chronic kidney disease, as well as explored the obstacles and solutions for effective trial designs.

The Medical Group Management Association offers an analysis of pending legislation that could help health care practices better serve patients.

Sickle cell disease (SCD) has known complications that include organ damage and failure, rhabdomyolysis, glaucoma, splenic sequestration, and vaso-occlusive crises. At present, the only potential cure is a bone marrow transplant, but it can be difficult to find a donor and there is a high rejection risk.

While response and safety may vary across racial and ethnic subgroups, progression-free survival and overall survival does not appear to differ when chimeric antigen receptor T-cell therapy is used in the treatment of patients with multiple myeloma.

High glucose variability in children and young adults with type 1 diabetes (T1D) strongly predicted slowed nerve conduction velocity, a forerunner of diabetic peripheral neuropathy, in a recent study.

The approval, which is based on results from the phase 3 KEYNOTE-966 trial, marks the sixth indication for pembrolizumab in gastrointestinal cancer.